The identification and the availability of a radioisotope for radiolabeling with properties and half-life that match with the pharmacokinetic of the radiopharmaceutical is crucial. Key collaborations with radiochemists at UBC, TRIUMF and the BC Cancer Agency allow developing methods for cyclotron-produced radioisotopes and purification as an attractive and practical substitution of reactors/generators, e.g 44Sc, 86Y and 61Cu 68Ga or 99mTc (actually available for patient SPECT imaging). We develop the production and the purification of 89Zr, an appealing PET radioisotope for antibody imaging. In addition, we have the unique access to 225Ac, from our partners at TRIUMF, to develop alpha-emitting conjugated agents.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.